The brand new pointers for the usage of monoclonal antibodies (mAbs) printed in Neurodegenerative Ailments, function exemplary medical suggestions for clinicians and healthcare suppliers, supporting the development of Alzheimer’s illness remedy in Switzerland.
The Swiss Reminiscence Clinics (SMC) community, a bunch of specialised clinics in Switzerland that diagnose and deal with sufferers with dementia, has launched new nationwide pointers on the usage of anti-amyloid mAbs – corresponding to Lecanemab and Donanemab – for treating Alzheimer’s illness in Switzerland. Lecanemab is now additionally licensed by the European Fee beneath strict situations.
Printed within the 11 April 2025 situation of Neurodegenerative Ailments, a Karger journal, the paper represents a coordinated effort by the SMC community to make sure protected, efficient, and moral implementation of those rising therapies. Serving as a medical observe information for clinicians and healthcare suppliers, it facilitates the implementation of rising remedy choices within the area of Alzheimer’s illness.
The paper outlines standards for affected person choice, biomarker affirmation, APOE genotyping, ARIA monitoring by way of MRI, and the infrastructure required to help protected remedy supply. It additionally emphasizes the significance of knowledgeable consent and recommends the creation of a nationwide affected person registry.
The rules stem from interdisciplinary discussions between clinicians within the SMC network–neurologists, geriatricians, old-age psychiatrists, neuropsychologists, neuroradiologists, and affected person organizations, together with representatives of educational and non-academic reminiscence clinics–between August 2023 and December 2024. They supply the primary country-specific framework for integrating mAbs into medical observe.
In a joint assertion, lead authors Dr. med Ansgar Felbecker and Professor Giovanni B. Frisoni, commented: “We constructed an skilled group of specialists to supply suggestions in Switzerland on when to make use of anti-amyloid monoclonal antibodies within the care of Alzheimer’s illness sufferers. Our hope is that this steerage will assist with the approval of those new medicine in different nations for sufferers who qualify for this care.”
Whereas the paper supplies a country-specific framework for the usage of mAbs in medical routine, the authors hope that as Alzheimer’s illness care enters a brand new therapeutic period, these pointers can stability innovation with medical accountability—providing a mannequin for different nations navigating comparable questions.
It’s nice that the journal Neurodegenerative Ailments serves as a house for such essential steerage that has the potential to affect hundreds of sufferers,”
Professor Gilles Allali, Editor in Chief of Neurodegenerative Ailments, Karger Publishers
“The newest pointers put ahead by Swiss consultants actually have the potential to remodel Alzheimer’s illness care throughout the globe.”